Strategies to improve the clinical performance of chimeric antigen receptor-modified T cells for cancer.
Strategies to improve the clinical performance of chimeric antigen receptor-modified T cells for cancer.
复制标题
DOI：
10.2174/156652313804806570
复制
发表时间：
2012-12
影响因子：
3.6
通讯作者：
Qing Zhang;Huizhong Li;Jie Yang;Liantao Li;Bao-fu Zhang;Jia Li;Junnian Zheng
中科院分区：
文献类型：
--
作者：
Qing Zhang;Huizhong Li;Jie Yang;Liantao Li;Bao-fu Zhang;Jia Li;Junnian Zheng
嵌合抗原受体(CAR)修饰的T细胞在血液系统恶性肿瘤中的临床试验显示前景看好。然而，在实体瘤中，临床反应并不那么令人印象深刻。重要的是确定如何进一步提高CAR修饰的T细胞的临床效果。在这篇综述中，我们重点介绍了最近的临床试验，并分析了决定临床反应的因素，包括：1)CAR的组成；2)CAR修饰T细胞的制备；3)临床治疗方案；4)患者的特征。我们还提出了在该技术可以应用于更广泛的临床应用之前必须进行研究的未来策略。
Clinical trials of chimeric antigen receptor (CAR)-modified T cells have shown promise in hematologic malignancies. However, in solid tumors, the clinical responses have been less impressive. It is important to determine how to further improve the clinical effects of CAR-modified T cells. In this review, we focus on recent clinical trials and analyze the factors that determine clinical responses, including the following: 1) the composition of the CAR; 2) the preparation of CAR-modified T Cells; 3) the clinical treatment schedule; 4) the patient characteristics. We also propose future Strategies that must be investigated before the technology can be used in a wider range of clinical applications.